GlassScriptPhysician profile
Jim Gould
NPI 1649200296
$706.22
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $129 · 2021: $144 · 2022: $83.26 · 2023: $153 · 2024: $61.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $130.10 | 2020-2021 | |
| Glaxosmithkline, LLC. | $84.27 | 2019-2023 | Shingrix |
| Pfizer INC. | $83.51 | 2020-2023 | |
| Ironshore Pharmaceuticals INC. | $65.98 | 2019-2020 | |
| Cranial Technologies, INC | $60.04 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $55.22 | 2019-2023 | Rotateq, Gardasil 9, M-M-R II |
| Adlon Therapeutics L.P. | $42.89 | 2019-2021 | |
| Corium, LLC | $38.90 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $26.14 | 2023 | |
| Supernus Pharmaceuticals, INC. | $24.62 | 2024 | Qelbree |
| Boston Scientific Corporation | $24.49 | 2023 | |
| Sobi, INC | $17.15 | 2023 | |
| Seqirus USA INC | $15.23 | 2022 | |
| Tris Pharma INC | $14.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.12 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Gould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.